Physician profile
Mackenzie Schumann
NPI 1063033900
$6,118.72
in general payments reported to CMS, 2019-2025
22 companies · $963 in 2025
The $963 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $1,264 · 2023: $2,432 · 2024: $808 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.64 |
| Education | $300.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,529.96 | 2021-2025 | |
| Janssen Biotech, INC. | $802.14 | 2023-2025 | Tremfya |
| Incyte Corporation | $600.10 | 2021-2023 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $549.24 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $504.35 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $369.21 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $360.34 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $314.59 | 2023-2025 | |
| Leo Pharma INC. | $259.65 | 2022-2023 | Adbry |
| Galderma Laboratories, L.P. | $179.53 | 2021-2025 | Dysport, Nemluvio |
| Vyne Pharmaceuticals INC. | $141.59 | 2021 | |
| Amgen INC. | $96.02 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.81 | 2024 | Cabtreo |
| Sun Pharmaceutical Industries INC. | $70.24 | 2023-2024 | Ilumya |
| Pfizer INC. | $56.02 | 2023-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $40.12 | 2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $39.60 | 2023-2024 | Zoryve |
| Organon LLC | $34.87 | 2025 | Vtama |
| Kerecis Limited | $23.15 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.83 | 2023 | Cyltezo |
| Phadia US INC. | $19.61 | 2023 | Immunocap |
| Mimedx Group, INC. | $17.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Schumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.